Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
They died 'doing what they loved': The stories of workers in their 80s who died on the job - 2Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- 3Watch interstellar comet 3I/ATLAS speed away from the sun in free telescope livestream on Nov. 16
- 4Why haven’t humans been back to the moon in over 50 years?
- 5Figurine of a woman and a goose offers peek at prehistoric beliefs
- The pace of hiring just fell to the lowest since 2011, outside of the pandemic
- This Overlooked Predator Is Running Out of Time—Why Conservationists Are Racing to Save the Striped Hyena
- Sally Rooney books may be withdrawn from UK sale over Palestine Action ban, court told
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- Ukraine demands army of 800,000 under peace plan
- Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- Bondi Beach survivor criticizes police for inaction during terror attack
- Amplifying Cash The executives: The Upsides and downsides of Various Ledgers
- Wegmans recalls mixed nuts over salmonella contamination fears
